NO20065146L - Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin - Google Patents

Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin

Info

Publication number
NO20065146L
NO20065146L NO20065146A NO20065146A NO20065146L NO 20065146 L NO20065146 L NO 20065146L NO 20065146 A NO20065146 A NO 20065146A NO 20065146 A NO20065146 A NO 20065146A NO 20065146 L NO20065146 L NO 20065146L
Authority
NO
Norway
Prior art keywords
atorvastatin
preparation
butyl ester
polymorphs
intermediates
Prior art date
Application number
NO20065146A
Other languages
English (en)
Inventor
Rok Zupet
Matej Smrkolj
Anton Stimac
Marija Grcman
Renata Jakse
Original Assignee
Krka Tovarna Zdravil Dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka Tovarna Zdravil Dd filed Critical Krka Tovarna Zdravil Dd
Publication of NO20065146L publication Critical patent/NO20065146L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er beskrevet krystallinsk formel 1 og 2 av atorvastatin tert.-butyl ester (formel II), fremgangsmåter for deres fremstilling og deres omdanning til høyrent atorvastatin hemi-kalsium i ikke-krystallinsk, spesielt amorft form.
NO20065146A 2004-04-09 2006-11-08 Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin NO20065146L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400112A SI21745A (sl) 2004-04-09 2004-04-09 Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
PCT/EP2005/003733 WO2005097742A1 (en) 2004-04-09 2005-04-08 Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin

Publications (1)

Publication Number Publication Date
NO20065146L true NO20065146L (no) 2006-11-08

Family

ID=34963800

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065146A NO20065146L (no) 2004-04-09 2006-11-08 Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin

Country Status (15)

Country Link
EP (1) EP1732886B1 (no)
CN (2) CN1946687B (no)
AT (1) ATE459602T1 (no)
DE (1) DE602005019703D1 (no)
DK (1) DK1732886T3 (no)
EA (1) EA010166B1 (no)
ES (1) ES2339570T3 (no)
HR (1) HRP20100217T1 (no)
NO (1) NO20065146L (no)
PL (1) PL1732886T3 (no)
PT (1) PT1732886E (no)
RS (1) RS51259B (no)
SI (2) SI21745A (no)
UA (1) UA86059C2 (no)
WO (1) WO2005097742A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
US20090081801A1 (en) * 2007-08-15 2009-03-26 Vinod Kumar Kansal Process for synthesis of pyrrole derivative, an intermediate for atorvastatin
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
SI2413911T1 (sl) 2009-03-31 2014-04-30 Krka, D.D., Novo Mesto Progresivna emulzijska kristalizacija
CN105693587A (zh) * 2016-01-15 2016-06-22 安徽悦康凯悦制药有限公司 一种阿托伐他汀钙的生产工艺
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
AU3289102A (en) * 2000-11-16 2002-06-11 Teva Pharma Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
TR200302281T2 (tr) * 2001-08-16 2004-09-21 Teva Pharmaceutical Industries Ltd. Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler

Also Published As

Publication number Publication date
ATE459602T1 (de) 2010-03-15
DK1732886T3 (da) 2010-06-14
RS51259B (sr) 2010-12-31
EA200601651A1 (ru) 2007-02-27
EP1732886A1 (en) 2006-12-20
DE602005019703D1 (de) 2010-04-15
PL1732886T3 (pl) 2010-08-31
PT1732886E (pt) 2010-03-12
CN101538238A (zh) 2009-09-23
WO2005097742A1 (en) 2005-10-20
CN1946687A (zh) 2007-04-11
UA86059C2 (ru) 2009-03-25
SI21745A (sl) 2005-10-31
CN1946687B (zh) 2011-09-28
SI1732886T1 (sl) 2010-06-30
CN101538238B (zh) 2012-08-29
HRP20100217T1 (hr) 2010-05-31
EP1732886B1 (en) 2010-03-03
ES2339570T3 (es) 2010-05-21
EA010166B1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
NO20065146L (no) Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin
WO2003086306A3 (en) 5ht2c receptor modulators
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20075809L (no) DNA-PK inhibitorer
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
NO20072930L (no) Tripentylcitrater og deres anvendelse
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TW200734311A (en) New compounds
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
TW200608966A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20065046L (no) Krystallinsk polymorf av bazedoksifenacetat
WO2005075467A3 (en) Crystalline forms of zolmitriptan
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
DK2229949T3 (da) Anvendelse af mælkesyrebakterier til nedsættelse af tandkødsblødning og reduktion af mundbetændelse
TW200734323A (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
TNSN07165A1 (en) Organic compounds
TW200635905A (en) Processes for producing 4-aminoquinazolines
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application